Preisverluste durch fehlenden Zusatznutzen
Definition
If IQWiG/G-BA finds no added benefit due to insufficient data, reimbursement is limited to reference price or standard treatment cost, directly impacting revenue from launch month 7.
Key Findings
- Financial Impact: Pricing capped at reference price (no higher than standard treatment); €5B total GKV-FinStG savings target
- Frequency: Applies from month 7 post-launch if no agreement
- Root Cause: Inadequate clinical trial data in dossiers
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
Pricing & Reimbursement Specialists, CEO, Commercial Leads
Deep Analysis (Premium)
Financial Impact
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Current Workarounds
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Get Solutions for This Problem
Full report with actionable solutions
- Solutions for this specific pain
- Solutions for all 15 industry pains
- Where to find first clients
- Pricing & launch costs
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
Kosten durch Datenqualitätsmängel in Experimenten
Kapazitätsverluste durch manuelle Datenprotokollierung
DSGVO-Risiken bei sensiblen Biotechnologie-Daten
Überwachungskosten für Fördermittelberichte
GoBD-Verstöße bei Fördermittel-Nachweisen
Strafen und Preisabschläge durch MFG-Nichteinhaltung
Request Deep Analysis
🇩🇪 Be first to access this market's intelligence